How to buy Eyenovia stock (EYEN)

Eyenovia is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.09 – an increase of 2.16% over the previous week. Eyenovia employs 57 staff and has a trailing 12-month revenue of around $31,405.

Our top picks for where to buy Eyenovia stock

Buy Eyenovia stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eyenovia stock price (NASDAQ: EYEN)

Use our graph to track the performance of EYEN stocks over time.

Eyenovia shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$0.09
52-week range	$0.08 - $2.57
50-day moving average more info button	$0.32
200-day moving average more info button	$0.70
Wall St. target price	$3.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.69

Is it a good time to buy Eyenovia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eyenovia price performance over time

Historical closes compared with the close of $0.09 from 2024-12-19

1 week (2024-12-13)	7.78%
1 month (2024-11-22)	-16.36%
3 months (2024-09-20)	-82.02%
6 months (2024-06-21)	-86.15%

1 year (2023-12-21)	-94.64%
2 years (2022-12-21)	-94.48%
3 years (2021-12-21)	4.06
5 years (2019-12-20)	3.86

Eyenovia financials

Revenue TTM	$31,405
Gross profit TTM	$12.4 million
Return on assets TTM	-92.94%
Return on equity TTM	-914.66%
Profit margin	0%
Book value	$0.20
Market Capitalization more info button	$9.3 million

TTM: trailing 12 months

Eyenovia share dividends

We're not expecting Eyenovia to pay a dividend over the next 12 months.

Eyenovia share price volatility

Over the last 12 months, Eyenovia's shares have ranged in value from as little as $0.077 up to $2.57. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 1.755. This would suggest that Eyenovia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Eyenovia overview

Eyenovia, Inc. , a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co. , Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi.

Frequently asked questions

null
What percentage of Eyenovia is owned by insiders or institutions?
Currently 9.995% of Eyenovia shares are held by insiders and 13.726% by institutions. How many people work for Eyenovia?
Latest data suggests 57 work at Eyenovia. When does the fiscal year end for Eyenovia?
Eyenovia's fiscal year ends in December. Where is Eyenovia based?
Eyenovia's address is: 295 Madison Avenue, New York, NY, United States, 10017 What is Eyenovia's ISIN number?
Eyenovia's international securities identification number is: US30234E1047 What is Eyenovia's CUSIP number?
Eyenovia's Committee on Uniform Securities Identification Procedures number is: 30234E104